547 Results for GLP-1 Pipeline Update
  • Trending Topics & Drug Approvals: May 2025

    May 22, 2025 – mepolizumab (Nucala) GlaxoSmithKline; an IL-5 antagonist monoclonal antibody New indication: add-on maintenance treatment of adults with inadequately controlled chronic obstructive...

  • Summer 2026 Prime Therapeutics Report

    Cover image Specialty insights to watch Prime Therapeutics /summer-2026-prime-therapeutics-report The Summer 2026 Prime Therapeutics Report delivers practical insights on the therapies, trends and...

    Prime Article: Research & Publications
  • Biosimilar basics part 4: How are biobetters and biosimilars different?

    Biobetters are just a nickname; they’re based on existing biologics but with a few key differences

    Prime Article: Perspectives
  • High-Cost Therapy Profile: October 2025

    Clinical deep dive Disease state overview WAS is a rare, X-linked, genetic disorder characterized by thrombocytopenia, eczema, immunodeficiency, and increased risk of autoimmunity and...

  • Oncology Insights: December 2025

    All brand names are property of their respective owners. References Kim SY, Park HS, Chiang AC. Small Cell Lung Cancer: A Review. JAMA. 2025;333(21):1906-1917. doi:10.1001/jama.2025.0560...

  • Oncology Insights: 2024 Rewind

    Last year, Oncology Insights brought you the most talked about topics in 2024. As we enter this new year, let us review these impactful and potentially practicing changing subjects that are likely...

  • AMCP Nexus 2024 - PDFs

    Methodological Framework for Propensity Adjusted Benchmarks for Pharmacy Key Performance Indicators The purpose of the study was to create a methodological framework for using propensity score...

  • High-Cost Therapy Profile: June 2024

    Clinical deep dive Disease state overview Myelodysplastic syndromes (MDS) are classified as disorders in which there are abnormal (dysplastic) hematopoietic stem cells in the bone marrow, leading...